Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.

@article{Barrett1996AllelicLO,
  title={Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.},
  author={Michael T. Barrett and Carissa A. Sanchez and Patricia C. Galipeau and K Neshat and Mary J. Emond and Brian J. Reid},
  journal={Oncogene},
  year={1996},
  volume={13 9},
  pages={1867-73}
}
High frequency allelic loss of chromosome 9p21 has been reported in a number of human cancers, including those of the esophagus. The CDKN2 gene on chromosome 9p21 that encodes the p16 inhibitor of cyclinD/Cdk4 complexes is a target of allelic loss and inactivation in a variety of human cancers and cell lines. However, the roles of 9p21 allelic losses and CDKN2 mutations in human neoplastic progression in vivo remain controversial. We determined the prevalence of allelic loss at 9p21 and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 59 extracted citations

Risk Stratification of Barrett's Esophagus: Updated Prospective Multivariate Analysis

The American Journal of Gastroenterology • 2004
View 2 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…